BRCA1 and BRCA2 gene mutations: Decision-making dilemmas concerning testing and management

Obstetrical and Gynecological Survey

Volumn 55, Issue 6, 2000, Pages 373-384

  Fasouliotis, Sozos J ^a   Schenker, Joseph G ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MASTECTOMY; MEDICAL DECISION MAKING; OVARIECTOMY; OVARY CANCER; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS;

DECISION MAKING; ETHICS, MEDICAL; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC SCREENING; HUMANS; MALE; MUTATION; NEOPLASMS; RISK FACTORS;

EID: 0034114851     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200006000-00023     Document Type: Review

References (83)

1. Lynch H, Krush A. Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 1971;133:644.
2. Schildkraut JM, Thompson WD. Familial ovarian cancer: A population-based case-control study. Am J Epidemiol 1988; 128:456.
3. Hall J, Lee M, Newman B et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990;250: 1684.
4. Miki Y, Swensen J, Shattuck-Eidens et al. A strong candidate for the breast ovarian cancer susceptibility gene BRCA-1. Science 1994;266:66.
5. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA-2. Nature 1995;378: 789.
6. Narod SA, Ford D, Deville P et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families: Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:254.
7. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5:1515.
8. Jensen RA, Thompson ME, Jetton TL et al. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 1996;55:303.
9. Scully R, Ganesan S, Brown M et al. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996;272: 123.
10. Gudas JM, Nguyen H, Li T et al. Hormone dependent regulation of BRCA1 in human breast cancer cells. Cancer 1995; 55:4561.
11. Boyd M, Harris F, McFarlane R et al. A human BRCA1 gene knockout. Nature 1995;375:541.
12. Holt JT, Thompson ME, Szabo CI et al. Growth retardation and tumor inhibition by BRCA-1. Nat Genet 1996;12:298.
13. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333.
14. Sharan S, Morimatsu M, Albrecht U et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA-2. Nature 1997;386:804.
15. Boyd J, Rubin S. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol 1997;64:196.
16. Serova O, Mazoyer S, Puget N et al. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer susceptibility genes? Am J Hum Genet 1997;60:486.
17. Shattuck-Eidens D, McClure M, Simard J et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: Implications for presymptomatic testing and screening. J Am Med Assoc 1995;273:535.
18. Phelan CM, Lancaster JM, Tonin P et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120.
19. Kuska B. Researchers expand genetic epidemiology of BRCA genes. J Natl Cancer Inst 1997;89:844.
20. Beller U, Halle D, Catane R et al. High frequency of BRCA1 and BRCA2 germline mutation in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997;67:123.
21. Motulsky AG. Jewish diseases and origins. Nat Genet 1995; 9:99.
22. Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14: 188.
23. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nat Genet 1995;11:198.
24. Berchuck A, Cirisano F, Lancaster JM et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996;175:738.
25. Castilla LH, Couch FJ, Erdos MR et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387.
26. Hogervorst FB, Cornelis RS, Bout M et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208.
27. Ford D, Easton DF, Bishop DT et al. Breast Cancer Linkage Consortium. Risks of cancer in BRCA1 mutation carriers. Lancet 1994;343:692.
28. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56:265.
29. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med 1996;334:1192.
30. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401.
31. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA-2. Nat Genet 1996;14:185.
32. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496.
33. Schubert EL, Lee MK, Mefford HC et al. BRCA2 in American families with four or more cases of breast or ovarian cancer. Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA-2. Am J Hum Genet 1997;60: 1031.
34. Krainer M, Silva-Arrieta S, Fitzgerald MG et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416.
35. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13:117.
36. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313.
37. Merajver SD, Pham TM, Caduff RF et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet 1995; 9:439.
38. Thompson ME, Jensen RA, Obermiller PS et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444.
39. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805.
40. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. J Am Med Assoc 1997;277:997.
41. Greenwald P, Nasca PC, Lawrence CE et al. Estimated effect of breast self-examination and routine physician examinations on breast cancer mortality. N Engl J Med 1978;299:271.
42. Mettler FA, Upton AC, Kelsey CA et al. Benefits versus risks from mammography. Cancer 1996;77:903.
43. Van Nagell JR, Higgins R, Donaldson E et al. Transvaginal sonography as a screening method for ovarian cancer. Cancer 1990;65:573.
44. Olt GJ, Berchuck A, Bast RC. Gynecologic tumor markers. Semin Surg Oncol 1990;6:305.
45. Mann GB, Borgen PI. Breast cancer genes and the surgeon. J Surg Oncol 1998;67:267.
46. Struewing JP, Watson P, Easton DF. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17:33.
47. NIH Consensus Development Panel on Ovarian Cancer Ovarian cancer: Screening, treatment, and follow-up. J Am Med Assoc 1995;273:491.
48. Tobacman JK, Greene MH, Tucker MA et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795.
49. Piver MS, Jishi MF, Tsukada Y et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751.
50. Hammond CB. Menopause and hormone replacement therapy: An overview. Obstet Gynecol 1996;87:2.
51. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 1991;265:1985.
52. Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995; 274:137.
53. Rebbeck TR, Couch FJ, Kant J et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA-2. Am J Hum Genet 1996;59:547.
54. Schrag D, Kuntz KM, Garber JE et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465.
55. Orlando R 3rd Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med 1997;337:787.
56. Birkmeyer JD, Welch HG. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med 1997;337:787.
57. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479.
58. Van Leeuwen FE, Benraadt J, Coeberg JW et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448.
59. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of twelve U.S. case-control studies, IV: the pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992;136:1212.
60. Piver MS, Baker TR, Jishi MF et al. Familial ovarian cancer: A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993;71:582.
61. Mettlin C, Jones G, Averette H et al. Defining and updating the American Cancer Society Guidelines for the cancer-related checkup. CA Cancer J Clin 1993;43:42.
62. Littrup PJ. Prostate cancer screening: Appropriate choices? Cancer 1994;74:2016.
63. Levin B, Murphy GP. Revision in American Cancer Society recommendations for the early detection of colorectal cancer. CA Cancer J Clin 1992;42:296.
64. Chaliki H, Loader S, Levenkron JC et al. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 1995;85:1133.
65. Lerman C, Seay J, Balshem A et al. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 1995;57:385.
66. Rubin SC, Blackwood A, Bandera C et al. BRCA-1, BRCA-2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population Relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998;178:670.
67. ACOG Committee Opinion. Breast-Ovarian Cancer Screening. Number 176. Int J Gynaecol Obstet 1997;56:82.
68. American Society of Human Genetics (ASHG) Ad Hoc Committee on Genetic Testing for Breast and Ovarian Cancer. Statement on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994;55:i.
69. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. J Am Med Assoc 1994;271:785.
70. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730.
71. Visco FM. Commentary on the ASCO statement on genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1737.
72. National Action Plan on Breast Cancer Commentary on the ASCO statement on genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1737.
73. Healy B. BRCA genes - Bookmaking, fortune telling, and medical care. N Engl J Med 1997;336:1448.
74. Skolnick M. Commentary on the ASCO statement on genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1737.
75. Schulman J, Stern H. Genetic predisposition testing for breast cancer. Cancer J Sci Am 1996;2:244.
76. Lapham E, Kozma C, Weiss J. Genetic discrimination: Perspectives of consumers. Science 1996;274:621.
77. Garber JE, Schrag D. Testing for inherited cancer susceptibility. J Am Med Assoc 1996;275:1928.
78. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 1994;154: 609.
79. Lynch H, Lynch J, Conway T. Psychological aspects of monitoring high-risk women for breast cancer. Cancer 1994;74:1184.
80. Lerman C, Narod S, Schulman K et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. J Am Med Assoc 1996;275:1885.
81. Schulman JD, Edwards RG. Preimplantation diagnosis is disease control, not eugenics. Hum Reprod 1996;11:463.
82. Lancaster JM, Wiseman RW, Berchuck A. An inevitable dilemma: Prenatal testing for mutations in the BRCA1 breast/ ovarian cancer susceptibility gene. Obstet Gynecol 1996;87: 306.
83. Fasouliotis SJ, Schenker JG. Preimplantation genetic diagnosis: Principles and ethics. Hum Reprod 1998;13:2238.